Linked Life Data

15585644

Source:http://linkedlifedata.com/resource/pubmed/id/15585644

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
23
pubmed:dateCreated
2004-12-8
pubmed:abstractText
In addition to their original function as cell cycle regulators, retinoblastoma (Rb) family members were recently reported to modulate the sensitivity of cancer cells to chemotherapeutic agents. The purpose of this study is to investigate the possible role of pRb2/p130 in the sensitivity of ovarian cancer to camptothecin, doxorubicin, and taxol.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/JNK Mitogen-Activated Protein..., http://linkedlifedata.com/resource/pubmed/chemical/MAP Kinase Kinase 4, http://linkedlifedata.com/resource/pubmed/chemical/Mitogen-Activated Protein Kinase..., http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel, http://linkedlifedata.com/resource/pubmed/chemical/Proteins, http://linkedlifedata.com/resource/pubmed/chemical/RBL2 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Retinoblastoma Protein, http://linkedlifedata.com/resource/pubmed/chemical/Retinoblastoma-Like Protein p130, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
8085-93
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:15585644-Adenoviridae, pubmed-meshheading:15585644-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15585644-Apoptosis, pubmed-meshheading:15585644-Blotting, Western, pubmed-meshheading:15585644-Camptothecin, pubmed-meshheading:15585644-Colony-Forming Units Assay, pubmed-meshheading:15585644-Doxorubicin, pubmed-meshheading:15585644-Drug Resistance, Neoplasm, pubmed-meshheading:15585644-Enzyme Activation, pubmed-meshheading:15585644-Female, pubmed-meshheading:15585644-Flow Cytometry, pubmed-meshheading:15585644-Humans, pubmed-meshheading:15585644-JNK Mitogen-Activated Protein Kinases, pubmed-meshheading:15585644-MAP Kinase Kinase 4, pubmed-meshheading:15585644-Mitogen-Activated Protein Kinase Kinases, pubmed-meshheading:15585644-Ovarian Neoplasms, pubmed-meshheading:15585644-Paclitaxel, pubmed-meshheading:15585644-Phosphorylation, pubmed-meshheading:15585644-Proteins, pubmed-meshheading:15585644-Retinoblastoma Protein, pubmed-meshheading:15585644-Retinoblastoma-Like Protein p130, pubmed-meshheading:15585644-Signal Transduction, pubmed-meshheading:15585644-Tumor Cells, Cultured, pubmed-meshheading:15585644-Tumor Suppressor Protein p53
pubmed:year
2004
pubmed:articleTitle
pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol.
pubmed:affiliation
Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, 1900 North 12th Street, Philadelphia, PA 19122, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't